Preclinical and clinical development of deferitrin, a novel, orally available iron chelator

Annals of the New York Academy of Sciences

Volumn 1054, Issue , 2005, Pages 492-494

  Donovan, Joanne M ^a   Plone, Melissa ^a   Dagher, Rafif ^a   Bree, Mark ^a   Marquis, Judith ^a  

^a Genzyme   (United States)

Author keywords

Deferitrin; GT56 252; Iron chelator; Toxicity; Transfusion therapy

Indexed keywords

BETA 2 MICROGLOBULIN; DEFERITRIN; IRON CHELATE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FECES LEVEL; DRUG RESEARCH; DRUG SAFETY; GENOTOXICITY; HUMAN; IRON CHELATION; IRON METABOLISM; IRON OVERLOAD; NEPHROTOXICITY; OPEN STUDY; PARALLEL DESIGN; PHASE 1 CLINICAL TRIAL; REPRODUCTIVE TOXICITY; TERATOGENICITY; THALASSEMIA MAJOR; THROMBOCYTOPENIA;

EID: 29744460870     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1345.071     Document Type: Conference Paper

References (3)

1. BERGERON, R.J., J. WIEGAND, J.S. MCMANIS, et al. 1999. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J. Med. Chem. 42: 2432-2440.
2. BREE, M.P., J.L. WAGNER, J. BELL & J.K. MARQUIS. 2004. Pharmacodynamics of repeat dose oral administration of GT56-252 in iron-loaded Cebus monkeys. Hematol. J. 5(Suppl. 2): S192.
3. DONOVAN, J.M., A. YARDUMIAN, K.A. GUNAWARDENA, et al. 2004. The safety and pharmacokinetics of deferitrin, a novel orally available iron chelator. Blood 104: 146-147a.